Taisho Pharmaceutical Holdings Co Ltd (TAIPY)
12.00
0.00 (0.00%)
USD |
OTCM |
Jun 26, 12:34
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 0.00 |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 29.25% |
Valuation | |
PE Ratio | 0.00 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.00 |
Price to Book Value | 0.00 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.0851 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 71.38% |
Profile
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan. |
URL | http://www.taisho-holdings.co.jp |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Mid Cap/Growth |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Sep. 28, 2023 |
Ratings
Profile
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan. |
URL | http://www.taisho-holdings.co.jp |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Mid Cap/Growth |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Sep. 28, 2023 |